Zentalis Pharmaceuticals, Inc. (ZNTL)
NASDAQ: ZNTL · Real-Time Price · USD
1.720
+0.010 (0.58%)
At close: Nov 6, 2026, 4:00 PM EST
1.730
+0.010 (0.58%)
After-hours: Nov 6, 2026, 7:30 PM EST
Zentalis Pharmaceuticals Employees
Zentalis Pharmaceuticals had 106 employees as of December 31, 2025. The number of employees decreased by 60 or 36.14% compared to the previous year. That makes Zentalis Pharmaceuticals the 31,099th largest employer in the world and 3,968th in the United States.
Employees
106
Change (1Y)
-60
Growth (1Y)
-36.14%
Revenue / Employee
n/a
Profits / Employee
-$1,316,462
Market Cap
162.84M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 106 | -60 | -36.14% |
| Dec 31, 2024 | 166 | -2 | -1.19% |
| Dec 31, 2023 | 168 | 12 | 7.69% |
| Dec 31, 2022 | 156 | -21 | -11.86% |
| Dec 31, 2021 | 177 | 53 | 42.74% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Entrada Therapeutics | 152 |
| Sutro Biopharma | 128 |
| Invivyd | 122 |
| BridgeBio Oncology Therapeutics | 88 |
| Upstream Bio | 75 |
| PepGen | 57 |
| ALX Oncology Holdings | 48 |
| Satellos Bioscience | 21 |
ZNTL News
- 5 days ago - Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 6 days ago - Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 10 days ago - Zentalis price target lowered to $7 from $8 at Mizuho - TheFly
- 16 days ago - Zentalis announces median OS data from DENALI Part 1b study - TheFly
- 16 days ago - Zentalis Pharmaceuticals Announces Meaningful Median Overall Survival Data in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer from DENALI Part 1b to be Presented at the ESMO Congress 2026 - GlobeNewsWire
- 21 days ago - Zentalis announces first OS data from DENALI part 1b study - TheFly
- 21 days ago - Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract - GlobeNewsWire
- 4 weeks ago - Zentalis assumed at Outperform from Market Perform at Leerink - TheFly